As per the new seven year supply agreement, Caliper Life Sciences is expected to continue to be the exclusive supplier of the microfluidic chips used in Agilent’s Bioanalyzer 2100 platform.
Caliper Life Sciences said that microfluidic technology enabled the development of instruments used in life science research and drug discovery clinical diagnostics, food testing, by eliminating manual steps, improving data quality and reproducibility, lowering overall costs, and speeding time to results.
Caliper Life Sciences president and CEO Kevin Hrusovsky said that they believe that their microfluidics technologies would continue growing as a tool for sample analysis as well as for sample preparation, particularly as sequencing and gene expression workflows become fundamental to the realisation of personalised medicine.